Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Plasminogen Activator, Urokinase Receptor

  • Hernán Trimarchi
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101811

Synonyms

Historical Background

In 1988 and 1989, respectively, Nielsen et al. and Estreicher et al. reported that the cell surface urokinase-type plasminogen activator (UPA) receptor was a 40- to 60-kD protein (Nielsen et al. 1988; Estreicher et al. 1989). Subsequent cloning of the human UPA receptor (uPAR) cDNA in 1990 showed that the primary structure of this receptor consists of 313 amino acid residues (Roldan et al. 1990). The entire uPAR sequence was found to be a triplicate of a cysteine-rich consensus sequence of about 90 amino acid residues suggesting that the origin of the uPAR might be an internal triplication of an ancestral gene (Behrendt et al. 1990, 1991).

uPAR is a receptor located in the plasma membrane of cells. However, one unusual feature of uPAR is its linkage to the plasma membrane via a...

This is a preview of subscription content, log in to check access.

References

  1. Aguirre Ghiso JA, Alonso DF, Farías EF, Gomez DE, de Kier Joffè EB. Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur J Biochem. 1999;263:295–304.CrossRefPubMedGoogle Scholar
  2. Alfano M, Sidenius N, Panzeri B, et al. Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication. Proc Natl Acad Sci U S A. 2002;99:8862–7.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Behrendt N, Ronne E, Ploug M, Petri T, Lober D, Nielsen LS, Schleuning W-D, Blasi F, Appella E, Dano K. The human receptor for urokinase plasminogen activator. J Biol Chem. 1990;265:6453–60.PubMedGoogle Scholar
  4. Behrendt N, Ploug M, Patthy L, Houen G, Blasi F, Dano K. The ligand-binding domain of the cell surface receptor for urokinasetype plasminogen activator. J Biol Chem. 1991;266:7842–7.PubMedGoogle Scholar
  5. Béné MC, Castoldi G, Knapp W, et al. EGIL, European Group on Immunological Classification of Leukemias. CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 2004;18:394–400.CrossRefPubMedGoogle Scholar
  6. Bhuvarahamurthy V, Schroeder J, Denkert C, et al. situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder. Oncol Rep. 2004;12:909–13.PubMedGoogle Scholar
  7. Bhuvarahamurthy V, Schroeder J, Kristiansen G, et al. Differential gene expression of urokinase type plasminogen activator and its receptor in human renal cell carcinoma. Oncol Rep. 2005;14:777–82.PubMedGoogle Scholar
  8. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist’s view. Thromb Haemost. 2007;97:336–42.CrossRefPubMedGoogle Scholar
  9. Bu G, Warshawsky I, Schwartz AL. Cellular receptors for plasminogen activators. Blood. 1994;83:3427–36.PubMedGoogle Scholar
  10. Cantero D, Friess H, Deflorin J, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer. 1997;75:388–95.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Chapman HA, Wei Y. Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb Haemost. 2001;86:124–9.CrossRefPubMedGoogle Scholar
  12. DanØ K, RØmer J, Nielsen BS, et al. Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue. J Leukoc Biol. 1999;66:40–9.CrossRefGoogle Scholar
  13. Estreicher A, Wohlwend A, Belin D, Schleuning W-D, Vassalli J-D. Characterization of the cellular binding site for the urokinase- type plasminogen activator. J Biol Chem. 1989;264:1180–9.PubMedGoogle Scholar
  14. Forbes K, Gillette K, Kelley LA, Sehgal I. Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis. World J Urol. 2004;1:67–71.CrossRefGoogle Scholar
  15. Gyetko MR, Sud S, Kendall T, et al. Urokinase receptor- deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol. 2000;165:1513–9.CrossRefPubMedGoogle Scholar
  16. Hamm LL, Feng Z, Hering-Smith KS. Regulation of sodium transport by ENaC in the kidney. Curr Opin Nephrol Hypertens. 2010;19:98–105.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Hildenbrand R, Gandhari M, Stroebel P, et al. The urokinase-system-role of cell proliferation and apoptosis. Histol Histopathol. 2008;23:227–36.PubMedGoogle Scholar
  18. Hjertner O, Qvigstad G, Hjorth-Hansen H, et al. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. Br J Haematol. 2000 June;109:815–22.CrossRefPubMedGoogle Scholar
  19. Hoyer-Hansen G, Ronne E, Solberg H, Behrendt N, Ploug M, Lund LR, Ellis V, Dano K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem. 1992;267:19224–9.Google Scholar
  20. Jankun J, Skrzypczak-Jankun E. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride. Cancer Biochem Biophys. 1999;17:109–23.PubMedGoogle Scholar
  21. Lester RD, Jo M, Montel V, Takimoto S, Gonias SL. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol. 2007;178:425–36.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Li Y, Cozzi PJ. Targeting uPA/uPAR in prostate cancer. Cancer-Treat Rev. 2007;33:521–7.CrossRefPubMedGoogle Scholar
  23. Loof TG, Deicke C, Medina E. The role of coagulation/fibrinolysis during Streptococcus pyogenes infection. Front Cell Infect Microbiol. 2014;4:art 128.CrossRefGoogle Scholar
  24. Ma HP, Eaton DC. Acute regulation of epithelial sodium channel by anionic phospholipids. J Am Soc Nephrol. 2005;16:3182–7.CrossRefPubMedGoogle Scholar
  25. Mazar AP, Ahn AP, O’Halloran TV. Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. Curr Pharm Des. 2011;17:1970–8.PubMedPubMedCentralCrossRefGoogle Scholar
  26. Mustjoki S, Alitalo R, Stephens RW, Vaheri A. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy. Thromb Haemost. 1999 May;81:705–10.CrossRefPubMedGoogle Scholar
  27. Nielsen LS, Kellerman GM, Behrendt N, Picone R, Dano K, Blasi F. A 55,000-60,000 M, receptor protein for urokinase-type plasminogen activator. J Biol Chem. 1988;263:2358–63.PubMedGoogle Scholar
  28. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator. J Biol Chem. 1991;266:1926–33.PubMedGoogle Scholar
  29. Pyke C, Ralfkiaer E, RØnne E, et al. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology. 1994;24:131–8.CrossRefPubMedGoogle Scholar
  30. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J. 1990;9:467–74.PubMedPubMedCentralCrossRefGoogle Scholar
  31. Sarra-Ferraris GM, Sidenius N. Urokinase plasminogen activator receptor: a functional integrator of extracellular proteolysis, cell adhesion, and signal transduction. Semin Thromb Hemost. 2013;39:347–55.CrossRefGoogle Scholar
  32. Schnaper HW, Barnathan ES, Mazar A, et al. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol. 1995;165:107–18.CrossRefPubMedGoogle Scholar
  33. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 2003;22:205–22.CrossRefPubMedPubMedCentralGoogle Scholar
  34. Suzuki S, Hayashi Y, Wang Y, et al. Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut. 1998;43:798–805.PubMedPubMedCentralCrossRefGoogle Scholar
  35. Svenningsen P, Bistrup C, Friis UG, Bertog M, Haerteis S, Krueger B, Stubbe J, Nørregaard Jensen O, Thiesson HC, Uhrenholt TR, Jespersen B, Jensen BL, Korbmacher C, Skøtt O. Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol. 2009;20:299–310.PubMedPubMedCentralCrossRefGoogle Scholar
  36. Trimarchi H. Plasmin, urokinase plasminogen activator receptor and amiloride in the nephrotic syndrome. Chapter 2. In: Mubarak M, editor. Nephrotic syndrome: etiology, pathogenesis and treatment. New York, USA: Nova Science Publishers, INTECH; 2015.Google Scholar
  37. Trimarchi H, Forrester M, Lombi F, Pomeranz V, Raña MS, Karl A, Andrews J. Amiloride as an alternate adjuvant antiproteinuric agent in Fabry disease. The potential roles of plasmin and uPAR. Case Rep Nephrol. 2014;(1–6):ID 854521.Google Scholar
  38. Trimarchi H, Canzonieri R, Muryan A, Schiel A, Araoz A, Paulero M, Andrews J, Rengel T, Forrester M, Lombi F, Pomeranz V, Iriarte R, Zotta E. Podocyturia. A clue for the rational use of amiloride in Alport renal disease. Case Rep Nephrol. 2016;1492743.Google Scholar
  39. Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J. Modification of kidney barrier function by the urokinase receptor. Nat Med. 2008;14:55–63.CrossRefPubMedGoogle Scholar
  40. Xia W, de Bock C, Murrell GA, Wang Y. Expression of urokinase-type plasminogen activator and its receptor is up-regulated during tendon healing. J Orthop Res. 2003;21:819–25.CrossRefPubMedGoogle Scholar
  41. Yamamoto M, Sawaya R, Mohanam S, et al. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res. 1994;54:5016–20.PubMedGoogle Scholar
  42. Zhang B, Xie S, Shi W, Yang Y. Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol Dial Transplant. 2012;27:1746–55.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Nephrology Service and Kidney Transplant UnitHospital Británico de Buenos AiresBuenos AiresArgentina